www.fdanews.com/articles/148692-acorda-reports-negative-top-line-results-of-study-exploring-ampyra-5mg-efficacy

Acorda Reports Negative Top Line Results of Study Exploring Ampyra 5mg Efficacy

August 14, 2012

Acorda Therapeutics has reported negative top line results from post-marketing commitment study exploring 5mg dose of Dalfampridine-ER in multiple sclerosis (MS) patients.
Pharmaceutical Business Review